JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.

While JAK inhibitors help in cessation of disease progression, they have no action on melanocyte proliferation; hence cannot result in re-pigmentation on their own. There is a need for tissue based JAK and cytokines based studies with post treatment expression data to validate the role of this class of drugs in vitiligo. There is as yet no good data to suggest that selective JAK inhibitors are superior to pan JAK inhibitors for vitiligo. But JAK inhibitors are useful in active disease and lack side effects caused by steroids which makes them singularly superior to oral steroids.